Cargando…
Tacrolimus (FK506) Prevents Early Stages of Ethanol Induced Hepatic Fibrosis by Targeting LARP6 Dependent Mechanism of Collagen Synthesis
Tacrolimus (FK506) is a widely used immunosuppressive drug. Its effects on hepatic fibrosis have been controversial and attributed to immunosuppression. We show that in vitro FK506, inhibited synthesis of type I collagen polypeptides, without affecting expression of collagen mRNAs. In vivo, administ...
Autores principales: | Manojlovic, Zarko, Blackmon, John, Stefanovic, Branko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670911/ https://www.ncbi.nlm.nih.gov/pubmed/23755290 http://dx.doi.org/10.1371/journal.pone.0065897 |
Ejemplares similares
-
Maculopathy Associated with Tacrolimus (FK 506)
por: Koh, Taehyuk, et al.
Publicado: (2011) -
Discovery and evaluation of inhibitor of LARP6 as specific antifibrotic compound
por: Stefanovic, Branko, et al.
Publicado: (2019) -
Advancing Nerve Regeneration: Translational Perspectives of Tacrolimus (FK506)
por: Daeschler, Simeon C., et al.
Publicado: (2023) -
Characterization of binding of LARP6 to the 5’ stem-loop of collagen mRNAs: Implications for synthesis of type I collagen
por: Stefanovic, Lela, et al.
Publicado: (2015) -
Association of long-term tacrolimus (FK506) therapy with abnormal megakaryocytosis, bone marrow fibrosis, and dyserythropoiesis
por: Yang, Zhongbo, et al.
Publicado: (2015)